Medical Device Clinical Evaluation: When Is It Needed?

This is one of the first major regulatory decisions a Medical Device startup has to make, and getting it wrong can be costly. A thorough Clinical Evaluation helps determine whether existing clinical evidence is sufficient or whether a new clinical investigation is needed. For Medical Device manufacturers, this assessment is essential to identifying evidence gaps before they affect regulatory submissions. Running an unnecessary study can waste valuable time and money, while overlooking an evidence gap can lead to delays when the Notified Body or FDA reviews the submission.

1. Start With the Regulatory Pathway, Not the Device

There is no one-size-fits-all answer. The need for clinical evidence depends on where you plan to market the device and how it is classified.

For example, a Class I device in the EU may face a very different evidence requirement from a novel Class III implant. Similarly, an FDA 510(k) with a strong predicate is different from a PMA, where clinical evidence is typically central to the application.

So, start by defining your target markets and regulatory classification. Once those are clear, you can determine what level of clinical evidence is actually needed.

2. Three Questions That Usually Settle It

2.1 Is there a genuinely equivalent, approved device with enough accessible data?
“Equivalent” means more than simply having a similar product. You need to consider the intended use, technology, and biological or clinical performance. The EU MDR and FDA use different regulatory frameworks, so the requirements are not identical.

For the EU, access to the comparator’s technical documentation can also be a challenge, especially when it belongs to a competitor.

2.2 Is there strong, directly relevant literature?

The evidence needs to relate closely to your device, technology, and intended population. Old, limited, or loosely related studies may not be enough for a Notified Body or FDA reviewer.

2.3 Is the intended use, population, or technology genuinely new?

A new indication, novel algorithm, first-of-its-kind technology, or under-studied population can increase the need for a clinical investigation.

If you lack a suitable comparator and strong supporting literature, while also introducing something genuinely new, a clinical investigation is much more likely. It is better to plan for it early than discover the requirement halfway through the regulatory review.

For IVD manufacturers, an IVD Clinical Evaluation can help determine whether existing analytical and clinical performance evidence adequately supports the intended purpose or whether additional clinical performance data is required.

3.A Simple Decision Framework

Strong predicate + strong literature + established technology → Investigation may not be needed: Existing evidence may be enough to support equivalence.

Partial predicate + some literature + incremental technology → Investigation may be needed: The decision depends on the available evidence and reviewer expectations. An early Q-Sub or scientific advice meeting can help.

No predicate + limited literature + novel technology or population → Investigation is more likely: Plan for clinical evidence early when there is a clear gap in existing data.

4. Signals That Increase the Need for Medical Device Clinical Evaluation

Higher-Likelihood Signals

Implantable or Class III devices: These often require stronger clinical evidence, particularly when existing data is limited.
Vulnerable populations:Paediatric or critical-care devices may need dedicated evidence when adult or general-population data cannot be reliably applied.

New intended use: A new indication or patient population can create a need for additional clinical evidence.

5. More Case-Dependent Signals

SaMD with novel AI/ML: A study may be needed when existing literature does not adequately support the algorithm or clinical claim.

AI/ML-based diagnostics: The need depends on whether relevant, directly applicable performance data already exists.

Novel combinations of functions: Additional evidence may be required when combining established technologies creates new clinical questions.

Ultimately, the need for a study depends on the evidence gap. The weaker the existing evidence for the specific device, claim, or population, the more likely a Medical Device clinical investigation will be required.

Why Deferring This Decision Is Expensive

Waiting until the technical file is nearly complete to address clinical evidence needs can become expensive. You may end up rushing a study to fill a late-stage evidence gap or receiving a Notified Body deficiency letter or FDA Additional Information request, which can add months to the timeline.

Addressing the clinical evidence question early, ideally before the design freeze, can help avoid both situations. A focused regulatory strategy discussion at this stage is relatively low-cost and can provide a clearer view of the evidence, budget, and timeline needed for market entry.

For Medical Device manufacturers, early Medical Device clinical evaluation planning can help align evidence generation with regulatory expectations and reduce the risk of costly submission delays.

If you are unsure where your device stands, a short regulatory strategy discussion can help clarify whether a Medical Device clinical investigation is likely to be needed — before, rather than after, the design is finalized.